with monoclonal anti-Ki-67 antibodies. The percentage of Ki-67 positive cells is determined in tumor hot spots where a minimum of 500 cells is counted. The mitotic index is the number of mitoses counted per high power field (HPF). Generally, mitoses are counted in 50 HPF and the mitotic index is expressed in mitoses per 10 HPF [5] .
The 2017 update for pancreatic NET altered the cutoff value for NET G1 and added a subclassification of G3 tumors dividing them into well-differentiated G3 NET and poorly-differentiated G3 neuroendocrine carcinomas (NEC). The different cut-off values are demonstrated in Table 1 [4].
The diagnosis and characterization of NET is based on both laboratory testing with serum markers such as Chromogranin A (and specific hormone levels for functional NET) and multimodality imaging. Different imaging techniques are available including ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI) and functional/nuclear imaging such as somatostatin receptor imaging and positron emission tomography (PET). The combination of PET and CT (PET/CT) with different tracers can be especially valuable in NET staging and detection of metastases. Fluorine 18 fluorodeoxyglucose (FDG) PET/CT tracer is widely used in oncologic imaging but appears to be of limited value in well-differentiated NET because of the near normal glucose turnover. NET that do not show a high uptake on 18 F-FDG-PET, can be investigated with a number of somatostatin analogs labelled with Gallium 68 ( 68 Ga) (i.e. 68 Ga-DOTA-NOC) which bind to the somatostatin receptors that are expressed at the cell membrane of NET. High grade NET are more often detected by 18 F-FDG PET/CT and thus FDG avidity can be an indicator of tumor aggressiveness [6] .
MRI has been used in the characterization of NET but mostly on a morphological, qualitative basis with evaluation of tumor size, borders, signal intensity, absence or presence of cystic or necrotic components, and enhancement pattern. More advanced MR imaging techniques such as diffusion-weighted imaging (DWI) and more importantly, quantitative evaluation of apparent diffusion coefficient (ADC) mapping may have an added value. The correlation of ADC values and tumor cellularity or aggressiveness/prognosis has been investigated extensively in other tumor types (i.e. prostate adenocarcinoma [7] and astrocytic brain tumors [8] ) where ADC values negatively correlate with tumor cellularity and aggressiveness.
Numerous small studies indicate that similar findings may apply to NET but validation of these studies is still needed [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
Purpose
To investigate the possible correlation between average and minimum ADC values of NET on MRI and the histopathological WHO grade and to determine if ADC values may help differentiate between low (G1 and G2) and high (G3) grade NET.
Materials and Methods

Case selection
For this retrospective study we included patients that were presented at the Multidisciplinary Neuroendocrine Tumor Board. This tumor board is part of a collaborative NETwork that has been set up between nine regional hospitals and the Antwerp University Hospital.
Ethical approval for this study was obtained from the Institutional Review Board (EC nr. 18/43/491) and informed consent was waived due to the retrospective nature of the study.
Elelectronic medical files from patients with a known NET discussed on the tumor board between November 2017 and April 2019 were analyzed retrospectively by a senior radiology resident and radiology staff member in consensus. Only patients with available MRI (primary tumor or metastasis), lesion size larger or equal to 1 cm, and known WHO tumor grade were included (n = 47).
Data collection and image analysis
First, the following clinical parameters were noted in an Excel worksheet: age, sex, primary tumor location, presence of metastasis, and WHO tumor grade (taken from pathology report).
Next, the technical parameters of the MRI exams were registered in the same worksheet (vendor, model, field strength, and employed b-values). This includes Siemens 1.5T (n = 29), Siemens 3T (n = 11), Philips 1.5T (n = 4), Philips 3T (1) and GE 1.5T (n = 2) with a b value sequence of 50-600-1000 sec/mm² and 0-1000 sec/mm² being the most frequently used.
The image analysis was done by a senior resident under supervision of a radiology staff member with more than ten years of experience in abdominal imaging. Measurements were performed on a picture archiving and The most notable differences of the 2010 and 2017 World Health Organization (WHO) classification system for NET is the increase of the Ki67-index cut-off value for G1 NET to <3 and the differentiation between well differentiated G3 NET and poorly differentiated G3 neuroendocrine carcinomas (NEC).
communicaion system (PACS) workstation suited for clinical use (GE RIS/PACS). Average and minimum ADC values (avgADC; minADC) were measured by drawing a freehand region of interest (ROI) on either the center slice of the lesion or the level with the least artifacts (Figures 1-3) . The T2-weighted images, DWI and contrast-enhanced T1-weighted images were used as a side by side reference. In case of multiple lesions (i.e. liver metastases) only the largest, most clearly delineated lesion was selected. The outermost border of the lesion and cystic or necrotic regions were omitted. In very large lesions with central necrosis, the ROI was drawn in the area with the highest intensity on the corresponding high b-value DWI series. In patients with MRI of both primary tumor and metastasis, separate ROIs were drawn for each and the corresponding ADC values were noted in the Excel worksheet. Data were first sorted by WHO grade group and subsequently grouped together into low grade NET (WHO G1 and G2) and high grade NET (WHO G3) for further statistical analysis. When ADC values of both primary tumor and metastasis were available, the values chosen for analysis were those that matched the origin of the histopathologic specimen (i.e. biopsy of liver metastasis: ADC values of metastasis).
Statistical analysis
Statistical analysis was conducted in SPSS Statistics (V25 -IBM). Non-parametric testing (Mann-Whitney-U) was used to compare differences in avgADC and minADC between low and high grade NET. Correlation between avgADC and minADC values and WHO grade was determined separately using R (V3. A significant difference was found between low-grade (G1+G2) and high-grade (G3) tumors (Mann-Whitney; avgADC: p < 0.001; minADC: p < 0.001). Separate, pairwise testing of WHO grades (Kruskal-Wallis) only showed a significant difference between G1 and G3 for both avgADC and minADC (p < 0.001). There was a moderate negative correlation between WHO-grade and avgADC/minADC 
Discussion
Treatment strategy for NET is related to the histological tumor grade and more specific the differentiation between low grade (WHO G1 and G2) and high grade (G3) tumors [11] . Low grade NET can be treated with surgical resection and/or targeted therapy for example somatostatin analogs, receptor targeted radionuclide agents, bevacizumab, sunitinib, and everolimus [3, 6]. High grade NET are treated with platinum-based chemotherapy. Alternative treatment strategies in inoperable patients include radiofrequency ablation, transarterial chemoembolization, and radioembolization. Both treatment strategy and prognosis are strongly dependent on histological grade with a poorer prognosis and higher metastatic rate for G3 tumors [9, 11] . The possibility to predict tumor grade on a noninvasive basis and without ionizing radiation would certainly be advantageous. Early risk stratification can help with disease management and prevents treatment delay. The purpose of this study was to evaluate the correlation of ADC values on MRI with the histopathologicaly based WHO grading. Our results show a significant difference in both avgADC and minADC values between low grade (G1+G2) and high grade (G3) NETs. These findings are in line with other studies that compared G1+G2 vs G3 NET [9, 11, 13, 14, 17, 18] . We chose to compare G1+G2 vs G3 because of the different treatment and prognosis of these groups as mentioned above. However, some studies have chosen to compare G1 vs. G2+G3 NET [10, 12] or compare each group separately [13, 14, 16, 19] . When comparing differences in avgADC between separate WHO grade groups we could only find a significant difference between G1 and G3 (p < 0.001) but not between G1 and G2 (p = 0.058) or G2 and G3 (p = 0.117). This was also the case for Pereira et al. [16] (G2 vs. G3) and Besa et al.
[9] (G1 vs. G2 and G2 vs. G3). Lotfalizadeh et al. [14] and Kulali et al. [13] found significant differences between all separate grade groups. Few studies include the minADC values like in our study [9, 14] . Besa et al. [9] found similar minADC values whereas Lotfalizadeh et al. [14] found higher minADC values ( Table 3) . We found a significant difference in minADC between low-grade (G1+G2) and high-grade (G3) NET and between G1 versus G3 NET (p < 0.001) when comparing groups separately. There was no significant difference in minADC between G1 and G2 (p = 0.110) and G2 and G3 (p = 0.089), similar to what Besa et al. reported [9] .
Min et al. [15] did not compare differences between groups but found a significant (p < 0.001) moderate negative correlation between avgADC and WHO grade (-0.57), in concordance with the negative correlation of -0.61 we found and the negative correlation of -0.55 Lotfalizadeh et al. reported [14] . Besa et al.
[9] found a significant but weaker negative correlation of -0.33. Others reported a negative correlation between avgADC and Ki67-index (Guo et al. [11] : -0.41, Wang et al. [17] : -0.70). The avgADC and minADC values we found per WHO grade were similar to the values found by previous studies and are summarized in Table 3 . Only the values acquired by Lotfalizadeh et al. [14] are markedly higher. The observed differences are probably multifactorial with not only tumor heterogeneity, relatively small sample size, technical differences (i.e. field strength, b-values), and measuring methods (i.e. center slice or volumetric). Expanding on the abovementioned technical differences, it is interesting to see that despite the different vendors, field-strengths, and b-values that were used, the acquired ADC values were similar to what most other authors found (some of them using only one device and some using multiple devices). We assume that the technical differences cause added noise in the data but are too small to have an effect on the final results. A direct comparison between vendors, field-strengths, and b-values would be interesting but is hard to achieve given the small sample size. Achieving similar results with different machines might facilitate the implementation of the acquired values in daily practice.
The decrease in ADC values in high-grade tumors can be attributed to the increased cellularity with decreased extracellular space and cytoplasmic volume (high nucleusto-cytoplasm ratio) restricting the movement of water molecules [16, 17] . Other factors such as fibrosis can also contribute to a lower ADC and might be an explanation for the lower ADC values in some low grade, well-differentiated tumors [17] .
We found a good accuracy of avgADC and minADC in predicting G3 vs G1+G2 NET with an AUC of 0.871 for both. Other studies found similar values: Besa et al. Table 4 . Our cut-off value for meanADC was similar to the one Guo et al. [11] found (≤0.950 × 10 -3 mm²/s) whereas other studies reported cut-off values that are slightly higher [9, 13, 14] . The SE and NPV for avgADC (both 100%) in our study were comparable but SP and PPV are lower. Only one study [9] reported a cut-off value for minADC (≤0.150 ×10 -3 mm²/s) which is markedly lower than the value we found (≤0.378 × 10 -3 mm²/s) and yielded lower SE, SP, PPV, and NPV. This difference in minADC value could be explained by the fact that the minimum value is only a single value that is more prone to artefacts and ROI placement than an average value.
We acknowledge several limitations of our study. First, the retrospective nature of the study comes with a number of disadvantages including selection bias, lack of standardization of imaging techniques and equipment, and possible influence of already initialized treatment. Secondly, ROI placement was performed in consensus and not repeated meaning intra-and interobserver agreement could not be tested. Image analysis was not entirely blinded for WHO-grade (as patients reviewed were discussed on the tumor board). Thirdly, although comparable to other studies, the sample size of G3 NET was relatively small. The latter can both be explained by the rarity of G3 tumors and the fact that during initial selection it became evident that most G3 patients did not have an MRI exam but had an 18 F-FDG-PET-CT followed by debulking or resection, often after neoadjuvant systemic treatment. Consequently G3 sample size was also too small to compare differences between G3 NET and G3 NEC as determined by the WHO 2017 criteria. Histopathologic grade was derived from the multidisciplinary staff report or pathology report without extra information about the cellularity or possible fibrosis, which could explain some of the heterogeneity (as reported by [17] ). Ki-67-index was often reported as a range instead of a single percentage making it unreliable for stratification. Histopathologic diagnosis was based on both surgical resection and biopsy, the latter being less reliable. We did not compare the ADC values to normal tissue/negative controls, however in some cases this would not have been possible (i.e. diffuse liver metastasis). Finally, the defined cut-off values and their corresponding predictive statistics should be interpreted with caution because of the small sample size and the unknown prevalence of G3 NET in the general population. The prevalence used to calculate PPV and NPV values is based on the prevalence of G3 NET in our study (19%), which is similar to the percentage found in larger population studies [2, 4] but this still needs to be verified. Average ADC value (avgADC), minimum ADC value (minADC), sensitivity (SE), specificity (SP), positive predictive value (PPV), negative predictive value (NPV).
